Welcome to our dedicated page for Doximity news (Ticker: DOCS), a resource for investors and traders seeking the latest updates and insights on Doximity stock.
Doximity reports news about its digital platform for U.S. medical professionals, including tools for clinical collaboration, medical news and research, career and on-call management, documentation workflows, and virtual patient visits. Company updates commonly cover quarterly financial results, platform engagement, workflow products, and AI-powered clinical reference and search capabilities.
Recurring developments also include Doximity Dialer telehealth recognition, physician research on AI adoption, and the integration of Pathway Medical into Doximity's clinical reference offerings. The company's news flow links product expansion with its verified medical-professional network and its role in digital workflow tools built for physicians.
Doximity (NYSE: DOCS) announced that Doximity Dialer was named the #1 Telehealth Video Conferencing Platform in the 2026 Best in KLAS Report for the fifth consecutive year, earning A-level ratings across categories and A+ for culture, loyalty, and value.
Engagement metrics show clinicians completed more than 300,000 Dialer calls each workday last quarter and a single-day record of 720,000 HIPAA-compliant calls and texts.
Doximity (NYSE: DOCS) reported fiscal 2026 third quarter results for the period ended December 31, 2025, with revenue of $185.1 million (up 10% YoY) and net income of $61.6 million (33.3% margin). Adjusted EBITDA was $111.4 million (60.2% margin). Operating cash flow was $60.9 million and free cash flow was $58.5 million. The company provided Q4 revenue guidance of $143–144 million and full-year revenue guidance of $642.5–643.5 million. The board authorized a $500 million share repurchase program.
Summary not available.
Doximity (NYSE:DOCS) reported fiscal 2026 second quarter results for the period ended September 30, 2025, showing continued platform growth and strong profitability.
Key figures: Revenue $168.5M (+23% YoY); Net income $62.1M (36.8% margin); Non-GAAP net income $90.0M (53.4% margin); Adjusted EBITDA $100.8M (+32% YoY, 59.8% margin); Operating cash flow $93.9M and Free cash flow $91.6M (both +37% YoY). The company said 650,000 prescribers used its workflow tools and AI Scribe/DoxGPT users grew >50% sequentially.
Guidance: Q3 revenue $180M–$181M and adjusted EBITDA $103M–$104M; FY26 revenue $640M–$646M and adjusted EBITDA $351M–$357M.
Doximity (NYSE:DOCS) will release fiscal 2026 second quarter results for the period ended September 30, 2025 after market close on November 6, 2025.
The company will host a conference call and live webcast at 2:00 p.m. PT / 5:00 p.m. ET. Investors can access the live audio webcast and a replay via the company’s Investor Relations website.
Doximity (NYSE:DOCS), the leading digital platform for U.S. medical professionals, has acquired Pathway Medical Inc. for a total potential value of $63 million, comprising $26 million in cash and up to $37 million in equity grants. The acquisition closed on July 29, 2025.
Pathway, a Montreal-based medical AI startup, brings significant assets to Doximity, including one of the largest structured medical datasets specifically built for AI. Their platform has demonstrated exceptional performance, achieving a 96% score on the USMLE benchmark. Notably, Pathway's premium product currently generates $300 per year from thousands of paying users.
The integration will enhance Doximity's clinical reference capabilities, with plans to offer Pathway's services for free to millions of users through Doximity's existing platform.
Doximity (NYSE: DOCS) reported strong fiscal 2026 first quarter results with revenue reaching $145.9 million, up 15% year-over-year. The company demonstrated robust profitability with net income of $53.3 million and a 36.5% margin.
Key highlights include operating cash flow of $62.1 million (up 51% YoY) and free cash flow of $60.1 million (up 52% YoY). The company's AI suite showed exceptional growth, increasing 5x year-over-year, while over 630,000 prescribers utilized their workflow tools.
Looking ahead, Doximity projects Q2 FY2026 revenue between $157-158 million and updated its full fiscal year 2026 guidance to $628-636 million in revenue.
Doximity (NYSE:DOCS) has released its 2025 Physician Compensation Report, revealing significant challenges in the healthcare workforce. The study, based on 230,000 survey responses over six years, shows physician compensation grew modestly by 3.7% overall, with a concerning 26% gender pay gap.
Key findings include men's compensation rising 5.7% versus 1.7% for women, significant pay disparities between pediatric subspecialists and adult-medicine counterparts, and surgical specialists earning 87% more than primary care physicians. The report highlights particular strain in pediatric care, with 90% of pediatricians concerned about reimbursement impacts on patient care.
The study also reveals broader workforce challenges, with 85% of physicians reporting being overworked and 77% willing to accept lower pay for better work-life balance.
Doximity (NYSE:DOCS), the leading digital platform for U.S. medical professionals, has scheduled its fiscal 2026 first quarter earnings release for August 7, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results.
Interested parties can access the live audio webcast through Doximity's Investor Relations page at investors.doximity.com. A replay of the webcast will be made available on the website following the call.
Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, has announced that its co-founder and CEO Jeff Tangney will be presenting at the William Blair 45th Annual Growth Stock Conference. The presentation is scheduled for Tuesday, June 3, 2025, at 4:40 p.m. Central Time.